☰

Brett M. Stevens, Ph.D. - Publications

Affiliations: 
2010 University of Rochester, Rochester, NY 
Area:
Glial development, multiple sclerosis, brain tumours
Tree Info Grants Similar researchers Related pubs Distance to... Nearest Nobel PubMed Report error

61 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2021 Amaya M, Inguva A, Pei S, Jones CL, Krug A, Ye H, Minhajuddin M, Winters AC, Furtek SL, Gamboni F, Stevens BM, D'Alessandro A, Pollyea DA, Reigan P, Jordan CT. The STAT3-MYC Axis Promotes Survival of Leukemia Stem Cells by Regulating SLC1A5 and Oxidative Phosphorylation. Blood. PMID 34525179 DOI: 10.1182/blood.2021013201  0.422
2021 Chavez JS, Rabe JL, Loeffler D, Higa KC, Hernandez G, Mills TS, Ahmed N, Gessner RL, Ke Z, Idler BM, Niño KE, Kim H, Myers JR, Stevens BM, Davizon-Castillo P, et al. PU.1 enforces quiescence and limits hematopoietic stem cell expansion during inflammatory stress. The Journal of Experimental Medicine. 218. PMID 33857288 DOI: 10.1084/jem.20201169  0.331
2020 Stevens BM, Jones CL, Pollyea DA, Culp-Hill R, D'Alessandro A, Winters A, Krug A, Abbott D, Goosman M, Pei S, Ye H, Gillen AE, Becker MW, Savona MR, Smith C, et al. Fatty acid metabolism underlies venetoclax resistance in acute myeloid leukemia stem cells. Nature Cancer. 1: 1176-1187. PMID 33884374 DOI: 10.1038/s43018-020-00126-z  0.327
2020 Walker ZJ, Idler B, Davis L, Stevens BM, VanWyngarden M, Ohlstrom D, Bearrows SC, Hammes A, Smith CA, Jordan CT, Mark TM, Forsberg PA, Sherbenou DW. Exploiting Protein Translation Dependence in Multiple Myeloma with Omacetaxine-based Therapy. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 33109736 DOI: 10.1158/1078-0432.CCR-20-2246  0.31
2020 Ye H, Minhajuddin M, Krug A, Pei S, Chou CH, Culp-Hill R, Ponder J, De Bloois E, Schniedewind B, Amaya ML, Inguva A, Stevens BM, Pollyea DA, Christians U, Grimes HL, et al. The hepatic microenvironment uniquely protects leukemia cells through induction of growth and survival pathways mediated by LIPG. Cancer Discovery. PMID 33028621 DOI: 10.1158/2159-8290.CD-20-0318  0.339
2020 Fisher MH, Kirkpatrick GD, Stevens BM, Jones CL, Callaghan MU, Rajpurkar M, Fulbright J, Cooper MA, Rowley J, Porter CC, Gutierrez-Hartmann A, Jones K, Jordan CT, Pietras EM, Di Paola J. ETV6 germline mutations cause HDAC3/NCOR2 mislocalization and upregulation of interferon response genes. Jci Insight. PMID 32841218 DOI: 10.1172/Jci.Insight.140332  0.314
2020 Jones CL, Stevens BM, Pollyea DA, Culp-Hill R, Reisz JA, Nemkov T, Gehrke S, Gamboni F, Krug A, Winters A, Pei S, Gustafson A, Ye H, Inguva A, Amaya M, et al. Nicotinamide Metabolism Mediates Resistance to Venetoclax in Relapsed Acute Myeloid Leukemia Stem Cells. Cell Stem Cell. PMID 32822582 DOI: 10.1016/J.Stem.2020.07.021  0.385
2020 Walker ZJ, VanWyngarden MJ, Stevens BM, Abbott D, Hammes A, Langouët-Astrie C, Smith CA, Palmer BE, Forsberg PA, Mark TM, Jordan CT, Sherbenou DW. Measurement of ex vivo resistance to proteasome inhibitors, IMiDs, and daratumumab during multiple myeloma progression. Blood Advances. 4: 1628-1639. PMID 32311014 DOI: 10.1182/Bloodadvances.2019000122  0.336
2020 Pei S, Pollyea DA, Gustafson A, Stevens BM, Minhajuddin M, Fu R, Riemondy KA, Gillen AE, Sheridan RM, Kim J, Costello JC, Amaya ML, Inguva A, Winters A, Ye H, et al. Monocytic Subclones Confer Resistance to Venetoclax-Based Therapy in Acute Myeloid Leukemia Patients. Cancer Discovery. PMID 31974170 DOI: 10.1158/2159-8290.Cd-19-0710  0.335
2019 Stevens BM, Zhang W, Pollyea DA, Winters A, Gutman J, Smith C, Budde E, Forman SJ, Jordan CT, Purev E. CD123 CAR T Cells for the Treatment of Myelodysplastic Syndrome. Experimental Hematology. PMID 31136781 DOI: 10.1016/J.Exphem.2019.05.002  0.396
2019 Hernandez G, Mills TS, Rabe JL, Chavez JS, Kuldanek S, Kirkpatrick G, Noetzli L, Jubair WK, Zanche M, Meyers JR, Stevens BM, Fleenor CJ, Adane B, Dinarello CA, Ashton J, et al. Pro-inflammatory cytokine blockade attenuates myeloid expansion in a murine model of rheumatoid arthritis. Haematologica. PMID 31101752 DOI: 10.3324/Haematol.2018.197210  0.355
2019 Jones CL, Stevens BM, D'Alessandro A, Culp-Hill R, Reisz JA, Pei S, Gustafson A, Khan N, DeGregori J, Pollyea DA, Jordan CT. Cysteine depletion targets leukemia stem cells through inhibition of electron transport complex II. Blood. PMID 31101624 DOI: 10.1182/Blood.2019898114  0.444
2019 Adane B, Ye H, Khan N, Pei S, Minhajuddin M, Stevens BM, Jones CL, D'Alessandro A, Reisz JA, Zaberezhnyy V, Gasparetto M, Ho TC, Kelly KK, Myers JR, Ashton JM, et al. The Hematopoietic Oxidase NOX2 Regulates Self-Renewal of Leukemic Stem Cells. Cell Reports. 27: 238-254.e6. PMID 30943405 DOI: 10.1016/J.Celrep.2019.03.009  0.459
2019 Gasparetto M, Pei S, Minhajuddin M, Stevens B, Smith CA, Seligman P. Low ferroportin expression in AML is correlated with good risk cytogenetics, improved outcomes and increased sensitivity to chemotherapy. Leukemia Research. 80: 1-10. PMID 30852438 DOI: 10.1016/J.Leukres.2019.02.011  0.385
2019 Fisher MH, Kirkpatrick G, Jones CL, Stevens BM, Callaghan M, Pietras E, Jones KL, Porter CC, Di Paola J. Germline Mutations in ETV6 are Associated with In Vivo cytoplasmic Localization of ETV6 and Cause Transcriptional Dysregulation of Interferon Response Genes Blood. 134: 2316-2316. DOI: 10.1182/Blood-2019-132032  0.362
2019 Pei S, Pollyea DA, Gustafson A, Minhajuddin M, Stevens BM, Ye H, Inguva A, Amaya ML, Krug A, Jones CL, Adane B, Winters A, Khan N, Ponder J, Schowinsky J, et al. Developmental Plasticity of Acute Myeloid Leukemia Mediates Resistance to Venetoclax-Based Therapy Blood. 134: 185-185. DOI: 10.1182/Blood-2019-131390  0.371
2019 Chavez J, Rabe JL, Higa K, Loeffler D, Nouraiz A, Mills T, Idler BM, Stevens BM, Fleenor C, Nerlov C, Nakajima H, Hagman J, Schroeder T, Kim HM, Jordan CT, et al. PU.1 Enforces Hematopoietic Stem Cell Quiescence during Chronic Inflammation Blood. 134: 822-822. DOI: 10.1182/Blood-2019-129300  0.445
2019 Kaner JD, Tavakkoli M, Toudic L, Stevens BM, Jordan CT, Taldone T, Chiosis G, Ritchie EK, Desai P, Samuel MB, Lee S, Roboz GJ, Guzman ML. PTPN11 Mutated Acute Myeloid Leukemia (AML) Features an Abundant Epichaperome Network and Is Sensitive to the Epichaperome Inhibitor PU-H71 Blood. 134: 3935-3935. DOI: 10.1182/Blood-2019-128276  0.358
2019 Jones CL, Stevens BM, Culp-Hill R, Dalessandro A, Krug A, Goosman M, Pei S, Pollyea DA, Jordan CT. Inhibition of Fatty Acid Metabolism Re-Sensitizes Resistant Leukemia Stem Cells to Venetoclax with Azacitidine Blood. 134: 1272-1272. DOI: 10.1182/Blood-2019-125773  0.421
2019 Winters A, Gutman JA, Purev E, Stevens BM, Pei S, Schowinsky J, Abbott D, Hammes A, Nakic M, Lyle L, Halsema K, Macero D, Hirose A, Boggs C, Falco A, et al. Venetoclax and Azacitidine for Older Newly Diagnosed Patients with Acute Myeloid Leukemia: A Single-Institution Pilot Study Using Measurable Residual Disease to Guide Therapy Blood. 134: 2638-2638. DOI: 10.1182/Blood-2019-122120  0.302
2019 Walker ZJ, Idler BM, VanWyngarden MJ, Stevens BM, Bearrows SC, Davis LN, Hammes A, Smith C, Jordan CT, Mark TM, Forsberg PA, Sherbenou DW. Broad Efficacy of the Translation Inhibitor Omacetaxine in Relapsed/Refractory Multiple Myeloma Samples Blood. 134: 4404-4404. DOI: 10.1182/Blood-2019-121937  0.459
2018 Jones CL, Stevens BM, D'Alessandro A, Reisz JA, Culp-Hill R, Nemkov T, Pei S, Khan N, Adane B, Ye H, Krug A, Reinhold D, Smith C, DeGregori J, Pollyea DA, et al. Inhibition of Amino Acid Metabolism Selectively Targets Human Leukemia Stem Cells. Cancer Cell. 34: 724-740.e4. PMID 30423294 DOI: 10.1182/Blood-2018-99-111965  0.397
2018 Pollyea DA, Stevens BM, Jones CL, Winters A, Pei S, Minhajuddin M, D'Alessandro A, Culp-Hill R, Riemondy KA, Gillen AE, Hesselberth JR, Abbott D, Schatz D, Gutman JA, Purev E, et al. Venetoclax with azacitidine disrupts energy metabolism and targets leukemia stem cells in patients with acute myeloid leukemia. Nature Medicine. PMID 30420752 DOI: 10.1038/S41591-018-0233-1  0.441
2018 Ye H, Adane B, Khan N, Alexeev E, Nusbacher N, Minhajuddin M, Stevens BM, Winters AC, Lin X, Ashton JM, Purev E, Xing L, Pollyea DA, Lozupone CA, Serkova NJ, et al. Subversion of Systemic Glucose Metabolism as a Mechanism to Support the Growth of Leukemia Cells. Cancer Cell. PMID 30270124 DOI: 10.1016/J.Ccell.2018.08.016  0.352
2018 Stevens BM, Khan N, D'Alessandro A, Nemkov T, Winters A, Jones CL, Zhang W, Pollyea DA, Jordan CT. Characterization and targeting of malignant stem cells in patients with advanced myelodysplastic syndromes. Nature Communications. 9: 3694. PMID 30209285 DOI: 10.1038/S41467-018-05984-X  0.481
2018 Pei S, Minhajuddin M, Adane B, Khan N, Stevens BM, Mack SC, Lai S, Rich JN, Inguva A, Shannon KM, Kim H, Tan AC, Myers JR, Ashton JM, Neff T, et al. AMPK/FIS1-Mediated Mitophagy Is Required for Self-Renewal of Human AML Stem Cells. Cell Stem Cell. PMID 29910151 DOI: 10.1016/J.Stem.2018.05.021  0.473
2018 Mills T, Hernandez G, Rabe JL, Kuldanek S, Chavez J, Kirkpatrick G, Noetzli L, Jubair W, Zanche M, Myers JR, Stevens BM, Fleenor C, Adane B, Ashton JM, Jordan CT, et al. Rheumatoid Arthritis Causes Hematopoietic Stem Cell Reprogramming to Maintain Functionality Blood. 132: 2573-2573. DOI: 10.1182/Blood-2018-99-120272  0.432
2018 Stevens BM, Jones CL, Winters A, Dugan J, Abbott D, Savona MR, Fesik SW, Pollyea DA, Jordan CT. PTPN11 Mutations Confer Unique Metabolic Properties and Increase Resistance to Venetoclax and Azacitidine in Acute Myelogenous Leukemia Blood. 132: 909-909. DOI: 10.1182/Blood-2018-99-119806  0.425
2018 Stevens BM, Winters A, Abbasi T, Singh NK, Ullal YS, Kumari I, Tyagi A, Alam A, Lunkad N, Drusbosky LM, Cogle CR, Vali S, Pollyea DA. WT1 and BCORL1 Identified By Computational Biology Modeling Analysis of Patient Genomics Are Novel Predictors of Response to Azacitidine (AZA) and Lenalidomide (LEN) Treatment in Acute Myeloid Leukemia (AML) Blood. 132: 1538-1538. DOI: 10.1182/Blood-2018-99-114429  0.352
2018 Jones CL, Stevens BM, D'Alessandro A, Culp-Hill R, Reisz J, Ye H, Khan N, Minhajuddin M, DeGregori J, Pollyea DA, Jordan CT. Cysteine and Cystine Depletion Targets Leukemia Stem Cells Blood. 132: 431-431. DOI: 10.1182/Blood-2018-99-113181  0.472
2018 Pollyea DA, Jones CL, Stevens BM, Pei S, D'Alessandro A, Culp-Hill R, Abbott D, Hammes A, Dugan J, Gutman JA, Purev E, Smith C, Jordan CT. Relapsed Acute Myeloid Leukemia Is Less Sensitive to Venetoclax + Azacitidine Due to Leukemia Stem Cell Resistance Driven By Fatty Acid Metabolism and Can be Overcome By Pharmacologic Inhibition of CPT1 Blood. 132: 432-432. DOI: 10.1182/Blood-2018-99-111507  0.319
2018 Walker ZJ, VanWyngarden MJ, Stevens BM, Langouët-Astrie C, Smith C, Palmer BE, Forsberg PA, Mark TM, Jordan CT, Sherbenou DW. A Rapid Functional Screen for Small Molecule and Monoclonal Antibody Drug Sensitivity in Multiple Myeloma Patients Blood. 132: 3203-3203. DOI: 10.1182/Blood-2018-99-111394  0.374
2018 Jones CL, Stevens BM, Culp-Hill R, Nemkov T, D'Alessandro A, Pei S, Pollyea DA, Jordan CT. Leukemia Stem Cells in Relapsed AML Patients Are Uniquely Dependent on Nicotinamide Metabolism Blood. 132: 429-429. DOI: 10.1182/Blood-2018-99-111366  0.454
2018 Winters A, Goosman M, Stevens BM, Purev E, Smith C, Pollyea DA, Jordan CT, Gutman JA. Tracking of AML-Associated Mutations Via Droplet Digital PCR Is Predictive of Outcomes Post-Transplant Blood. 132: 2138-2138. DOI: 10.1182/Blood-2018-99-110834  0.321
2017 Zhang W, Stevens BM, Budde EE, Forman SJ, Jordan CT, Purev E. Anti-CD123 CAR T-Cell Therapy for the Treatment of Myelodysplastic Syndrome Blood. 130: 1917-1917. DOI: 10.1182/Blood.V130.Suppl_1.1917.1917  0.384
2017 Pollyea DA, Stevens BM, Winters A, Minhajuddin M, Gutman JA, Purev E, Smith C, Abbott D, Jordan CT. Venetoclax (Ven) with Azacitidine (Aza) for Untreated Elderly Acute Myeloid Leukemia (AML) Patients (Pts) Unfit for Induction Chemotherapy: Single Center Clinical Experience and Mechanistic Insights from Correlative Studies Blood. 130: 181-181. DOI: 10.1182/Blood.V130.Suppl_1.181.181  0.359
2016 Pei S, Minhajuddin M, D'Alessandro A, Nemkov T, Stevens BM, Adane B, Khan N, Hagen FK, Yadav VK, De S, Ashton JM, Hansen KC, Gutman JA, Pollyea DA, Crooks PA, et al. Rational Design of a Parthenolide-based Drug Regimen that Selectively Eradicates Acute Myelogenous Leukemia Stem Cells. The Journal of Biological Chemistry. PMID 27573247 DOI: 10.1074/Jbc.M116.750653  0.479
2016 Ho TC, LaMere M, Stevens BM, Ashton JM, Myers JR, O'Dwyer KM, Liesveld JL, Mendler JH, Guzman M, Morrissette JD, Zhao J, Wang ES, Wetzler M, Jordan CT, Becker MW. Evolution of acute myelogenous leukemia stem cell properties following treatment and progression. Blood. PMID 27421961 DOI: 10.1182/Blood-2016-02-695312  0.431
2016 Ye H, Adane B, Khan N, Sullivan T, Minhajuddin M, Gasparetto M, Stevens B, Pei S, Balys M, Ashton JM, Klemm DJ, Woolthuis CM, Stranahan AW, Park CY, Jordan CT. Leukemic Stem Cells Evade Chemotherapy by Metabolic Adaptation to an Adipose Tissue Niche. Cell Stem Cell. PMID 27374788 DOI: 10.1016/J.Stem.2016.06.001  0.425
2016 Riedel SS, Haladyna JN, Bezzant M, Stevens B, Pollyea DA, Sinha AU, Armstrong SA, Wei Q, Pollock RM, Daigle SR, Jordan CT, Ernst P, Neff T, Bernt KM. MLL1 and DOT1L cooperate with meningioma-1 to induce acute myeloid leukemia. The Journal of Clinical Investigation. PMID 26927674 DOI: 10.1172/Jci80825  0.367
2016 Stevens BM, Pollyea DA, Khan N, Jordan CT. Distinct Metabolic Properties of MDS Stem Cells Provide Novel Opportunities for Therapeutic Intervention Blood. 128: 4316-4316. DOI: 10.1182/Blood.V128.22.4316.4316  0.505
2016 Pei S, Minhajuddin M, Adane B, Stevens BM, Khan N, D'alessandro A, Nemkov T, Hansen KC, Pollyea DA, Jordan CT. Mitochondrial Fission 1 Regulates GSK3 and AMPK Signaling to Sustain Leukemia Stem Cell Function in Acute Myelogenous Leukemia Blood. 128: 1703-1703. DOI: 10.1182/Blood.V128.22.1703.1703  0.421
2016 Adane B, Ye H, Pei S, Khan N, Minhajuddin M, Stevens BM, Zaberezhnyy V, Pollyea DA, Jordan CT. The Role of NADPH Oxidase 2 in Normal and Malignant Hematopoiesis Blood. 128: 1079-1079. DOI: 10.1182/Blood.V128.22.1079.1079  0.487
2016 Riedel S, Haladyna J, Stevens B, Pollyea D, Wei Q, Jordan C, Ernst P, Neff T, Bernt K. Abstract IA11: Meningioma-1 cooperates with MLL and DOT1L to induce leukemia Cancer Research. 76. DOI: 10.1158/1538-7445.Pedca15-Ia11  0.397
2015 Stevens B, Maxson J, Tyner J, Smith CA, Gutman JA, Robinson W, Jordan CT, Lee CK, Swisshelm K, Tobin J, Wei Q, Schowinsky J, Rinella S, Lee HG, Pollyea DA. Clonality of Neutrophilia Associated with Plasma Cell Neoplasms: Report of a SETBP1 Mutation and Analysis of a Single Institution Series. Leukemia & Lymphoma. 1-22. PMID 26389776 DOI: 10.3109/10428194.2015.1094697  0.334
2015 Alvarez-Calderon F, Gregory MA, Pham-Danis C, DeRyckere D, Stevens BM, Zaberezhnyy V, Hill AA, Gemta L, Kumar A, Kumar V, Wempe MF, Pollyea DA, Jordan CT, Serkova NJ, Graham DK, et al. Tyrosine kinase inhibition in leukemia induces an altered metabolic state sensitive to mitochondrial perturbations. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 21: 1360-72. PMID 25547679 DOI: 10.1158/1078-0432.Ccr-14-2146  0.395
2015 Noble M, Mayer-Pröschel M, Li Z, Dong T, Cui W, Pröschel C, Ambeskovic I, Dietrich J, Han R, Yang YM, Folts C, Stripay J, Chen HY, Stevens BM. Redox biology in normal cells and cancer: restoring function of the redox/Fyn/c-Cbl pathway in cancer cells offers new approaches to cancer treatment. Free Radical Biology & Medicine. 79: 300-23. PMID 25481740 DOI: 10.1016/J.Freeradbiomed.2014.10.860  0.52
2015 Ye H, Adane B, Khan N, Ashton JM, Balys M, Stevens BM, Minhajuddin M, Jordan CT. Adipose Tissue Functions As a Reservoir for Leukemia Stem Cells and Confers Chemo-Resistance Blood. 126: 845-845. DOI: 10.1182/Blood.V126.23.845.845  0.386
2015 Pei S, Minhajuddin M, Stevens BM, Adane B, Khan N, D'alessandro A, Nemkov T, Hansen KC, Pollyea D, Jordan CT. Regulation of Mitochondrial Morphology Is Important for Leukemia Stem Cell Function Blood. 126: 842-842. DOI: 10.1182/Blood.V126.23.842.842  0.444
2015 Stevens BM, Pollyea D, Khan N, Jordan CT. Characterization and Targeting of Myelodysplastic Syndrome Stem Cells Blood. 126: 4104-4104. DOI: 10.1182/Blood.V126.23.4104.4104  0.443
2015 Riedel S, Haladyna J, Stevens B, Jordan CT, Pollyea D, Armstrong SA, Wei Q, Ernst P, Neff T, Bernt KM. Meningeoma-1 Cooperates with MLL and DOT1L to Induce Leukemia Blood. 126: 2428-2428. DOI: 10.1182/Blood.V126.23.2428.2428  0.379
2015 Stripay JL, Stevens BM, Bardin AL, Noble MD. Abstract B14: Targeting a network of cancer control nodes through rescue of c-Cbl: A novel therapeutic approach in GBM Brain. 75. DOI: 10.1158/1538-7445.Brain15-B14  0.581
2014 Stevens BM, Folts CJ, Cui W, Bardin AL, Walter K, Carson-Walter E, Vescovi A, Noble M. Cool-1-mediated inhibition of c-Cbl modulates multiple critical properties of glioblastomas, including the ability to generate tumors in vivo. Stem Cells (Dayton, Ohio). 32: 1124-35. PMID 24458840 DOI: 10.1002/Stem.1644  0.72
2014 Riedel S, Bernt KM, Haladyna J, Bezzant M, Stevens B, Pollyea DA, Sinha AU, Armstrong SA, Wei Q, Jordan CT, Neff T. Targeting Meningeoma-1 Driven AML through Epigenetic Modulation of the Cell of Origin Blood. 124: 838-838. DOI: 10.1182/Blood.V124.21.838.838  0.432
2013 Chen HY, Yang YM, Stevens BM, Noble M. Inhibition of redox/Fyn/c-Cbl pathway function by Cdc42 controls tumour initiation capacity and tamoxifen sensitivity in basal-like breast cancer cells. Embo Molecular Medicine. 5: 723-36. PMID 23606532 DOI: 10.1002/Emmm.201202140  0.682
2013 Stevens BM, Folts CJ, Chen W, Bardin AL, Noble M. Abstract 4106: Cool-1-mediated inhibition of c-Cbl as a therapuetic target, which modulates multiple critical properties of glioblastomas. Cancer Research. 73: 4106-4106. DOI: 10.1158/1538-7445.Am2013-4106  0.689
2013 Chen H, Yang Y, Stevens B, Noble M. Abstract 2912: Inhibition of redox/Fyn/c-Cbl pathway function by Cdc42 controls tumor initiation capacity and tamoxifen sensitivity in basal-like breast cancer cells. Cancer Research. 73: 2912-2912. DOI: 10.1158/1538-7445.Am2013-2912  0.696
2012 Stevens BM, Folts CJ, Bardin AL, Noble M. Abstract 2074: Cool-1-mediated inhibition of c-Cbl modulates multiple critical properties of glioblastomas, including the ability to generate tumorsin vivo Cancer Research. 72: 2074-2074. DOI: 10.1158/1538-7445.Am2012-2074  0.684
2011 Stevens BM, Folts CJ, Bardin AL, Noble M. Abstract 1007: The Redox/Fyn/c-Cbl pathway and its interaction with Cool-1: A novel pathway that regulates chemosensitivity in glioblastoma Cancer Research. 71: 1007-1007. DOI: 10.1158/1538-7445.Am2011-1007  0.667
2009 Stevens B, Folts C, Cui W, Noble M. Abstract A159: The Redox/ Fyn/c‐Cbl pathway and its interaction with Cool‐1: A novel pathway that regulates chemosensitivity in glioblastoma Molecular Cancer Therapeutics. 8. DOI: 10.1158/1535-7163.Targ-09-A159  0.65
2008 Wang PY, Young F, Chen CY, Stevens BM, Neering SJ, Rossi RM, Bushnell T, Kuzin I, Heinrich D, Bottaro A, Jordan CT. The biologic properties of leukemias arising from BCR/ABL-mediated transformation vary as a function of developmental origin and activity of the p19ARF gene. Blood. 112: 4184-92. PMID 18755985 DOI: 10.1182/Blood-2008-02-142190  0.471
Show low-probability matches.